MORRISVILLE – In new research findings published in the Journal of the American College of Cardiology (JACC) Cardiovascular Imaging, scientists found that the technology developed by Triangle startup Myocardial Solutions was able to differentiate between healthy patients and patients who were at risk of heart failure though they were not displaying symptoms.
MyoStrain, which has received FDA-510(k) pre-market clearance and is commercially available in the United States and in Europe, is a proprietary MRI software developed by the company. The technology provides clinicians with novel cardiac information to proactively detect, manage and monitor patient heart health, according to a spokesperson for the company, Ahmed Osman. The process takes less than 10 minutes and is non-invasive, and yields a personalized patient heart health report.
What Are the Benefits of Fish Oil for Memory? everydayhealth.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from everydayhealth.com Daily Mail and Mail on Sunday newspapers.
April 19, 2021
For patients with heart failure, the risk of dying after an episode of pneumonia is up to fourfold higher than if they had not contracted the disease, with the risk for vascular events and death remaining high for months after recovery, according to a post hoc analysis of the PARADIGM-HF and PARAGON-HF trials.
While pneumonia is typically considered an acute illness, prior research has documented a link to subsequent ACS; whether it can also exert long-term risks for heart failure was unclear, the authors say. And while pneumonia vaccines against the two most-common strains are widely available and vaccination is recommended in HF guidelines, uptake has been poor.
COVID Plus MI Confers Poor Prognosis; 1 in 3 Die in Hospital medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.